“These exciting organizational updates further position BioAgilytix to scale efficiently and meet growing customer needs, all while taking full advantage of the additional capital and resources our new owner Cobepa brings to our company,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “The strength of our leadership team is only reinforced by these internal promotions, and we continue to have several of the most respected experts in the field of large molecule bioanalysis guiding our strategic path forward.”
Dr. Kromminga is an esteemed immunologist with more than 20 years’ expertise covering the entire cascade of assay strategy and characterization of immune responses against biological therapeutics. He became BioAgilytix’s European Chief Scientific Officer in 2016 after the company he founded, IPM Biotech, was acquired by BioAgilytix. Dr. Kromminga led IPM Biotech to become a pioneer in immunogenicity, bringing the first biosimilar EPO to approval in Europe and supporting the first biosimilar EPO submission in the USA. Today, as a world-leading authority in the area of immunogenicity, he is invited to speak at numerous international scientific conferences and has authored multiple peer-reviewed scientific publications in journals and text books. In the role of Global Chief Scientific Officer, Dr. Kromminga will ensure BioAgilytix is fully equipped to continue delivering its industry-leading level of scientific excellence. “I am thrilled that Arno will be leading BioAgilytix’s global scientific strategy moving forward,” said Dr. Afshin Safavi, BioAgilytix’s Founder. “I will be staying on with BioAgilytix as a Board member and have every confidence that he will continue to guide our business to effectively meet customers’ evolving and expanding bioanalytical needs with premium science and high-quality results.”
Ms. Heinz has more than 15 years’ commercial experience with a strategic pharma background as well as several years of in-lab experience. She joined BioAgilytix in 2016 and has been instrumental in leading the business development team to achieve record sales growth backed by strong operational processes. As Vice President of Global Business Development, Ms. Heinz joins BioAgilytix’s executive team and will forge strategies to ensure the company is able to continue to scale its growth in both USA and Europe.
“It is critical that our team is solidly positioned to take advantage of the new resources infused by Cobepa, so that we can capitalize on opportunities for expansion while upholding our ongoing commitment to effective communications and scientific excellence,” added Datin. “Arno and Beth have all proven their commitment to this mission, as well as their ability effectively to execute against it, and I am excited to see where we can take BioAgilytix together in 2019 and beyond.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.